Defcort 30 mg (Deflazacort)

Product Overview

Defcort 30 mg is a prescription corticosteroid tablet produced by Macleods Pharmaceuticals Pvt Ltd. Each strip contains ten tablets, and the product is marketed in pack sizes of thirty, sixty, and ninety tablets to suit chronic therapy needs. The medication is formulated for the treatment of severe allergic reactions, providing a rapid anti‑inflammatory effect when systemic control is required. Packaging is designed to protect the tablets from moisture, and the strip format allows for easy dispensing in clinical or home settings. The active ingredient, deflazacort, belongs to a class of glucocorticoids that have been studied for their potency and reduced sodium retention compared with some other steroids. For more detailed regulatory information, see the U.S. Food and Drug Administration label database or the National Institutes of Health resources on corticosteroid therapy.

What is Defcort 30 mg (Deflazacort)

Defcort 30 mg contains deflazacort, a synthetic glucocorticoid with anti‑inflammatory, immunosuppressive, and antiallergic properties. The drug is classified as a moderate‑potency steroid that exerts its effects by binding to intracellular glucocorticoid receptors and modulating gene transcription pathways involved in immune activation. Although the precise molecular weight is not listed in consumer labeling, the active moiety is well documented in pharmacopeial references. The medication is indicated for patients experiencing acute or chronic severe allergic episodes that do not respond adequately to antihistamines or topical treatments. Clinical guidelines often recommend its use when a rapid reduction of swelling, itching, or urticaria is necessary, especially in cases of anaphylaxis adjunct therapy or chronic urticaria. Additional scientific context can be found on MedlinePlus, a service of the U.S. National Library of Medicine.

Uses and Benefits

The primary benefit of Defcort 30 mg is its ability to suppress excessive immune activity that drives severe allergic manifestations such as angioedema, serum sickness, or refractory dermatitis. By attenuating cytokine production and mast cell degranulation, the drug helps to relieve symptoms like swelling, pain, and skin eruptions within hours of administration. In addition, the steroid’s longer half‑life compared with some short‑acting agents allows for once‑daily dosing in many regimens, improving adherence. Patients with autoimmune skin conditions that overlap with allergic inflammation may also experience improvement. Because the medication is available in multiple pack sizes, clinicians can tailor the supply to treatment length, reducing the need for frequent pharmacy visits. Real‑world usage data are reviewed in peer‑reviewed journals indexed by PubMed, which can help patients understand expected outcomes.

How It Works

Deflazacort exerts its therapeutic effect by crossing cell membranes and binding to cytosolic glucocorticoid receptors. This complex then translocates to the nucleus, where it interacts with DNA response elements to modulate the expression of genes responsible for inflammation, immune cell trafficking, and vascular permeability. The resulting biochemical cascade leads to decreased production of prostaglandins, leukotrienes, and other mediators that amplify allergic responses. Unlike some steroids, deflazacort is metabolized primarily in the liver and excreted through the kidneys, which influences dosing adjustments in patients with hepatic or renal impairment. The drug’s selectivity for anti‑inflammatory pathways over mineralocorticoid activity reduces the likelihood of fluid retention, a consideration for long‑term therapy. For an in‑depth scientific review, refer to the National Center for Biotechnology Information database.

Dosage Guidelines

Dosage of Defcort 30 mg is individualized based on the severity of the allergic condition, patient weight, and concurrent therapies. Typical adult regimens start with one tablet daily for a short induction period, followed by a taper that may span several days to weeks depending on clinical response. Pediatric dosing is calculated per kilogram of body weight and must be prescribed by a qualified healthcare professional. Tablets should be taken with food to minimize gastrointestinal irritation, and patients are advised not to crush or chew the tablet. If a dose is missed, the patient should not double up but rather resume the regular schedule. Chronic use requires periodic evaluation of blood pressure, blood glucose, and bone density, as prolonged steroid exposure can affect these parameters. Detailed dosing algorithms are available through clinical practice guidelines hosted by reputable medical societies.

Side Effects

Like all corticosteroids, Defcort 30 mg can produce adverse effects, although many are mild and transient. Common side effects include increased appetite, mild insomnia, and temporary mood changes. Less frequent but clinically important reactions may involve elevated blood pressure, elevated blood glucose, and electrolyte imbalances. Rarely, patients may experience gastrointestinal ulceration, psychiatric disturbances, or allergic hypersensitivity to the tablet excipients. It is essential for patients to report any new or worsening symptoms to their prescribing clinician promptly. The FDA maintains a safety database that lists reported events, and clinicians can access this information to assess risk versus benefit. Monitoring parameters such as fasting glucose and lipid profile is recommended during extended treatment courses.

Warnings and Precautions

Defcort 30 mg is contraindicated in individuals with known hypersensitivity to deflazacort or any component of the tablet formulation. Patients with active or historical infections, especially viral diseases such as chickenpox or measles, should avoid steroid therapy unless a physician determines that the benefit outweighs the risk. Caution is advised in pregnancy and lactation; while some studies suggest low risk, the decision must be made by a healthcare provider. Drug interactions can occur with immunosuppressants, anticoagulants, and certain antihypertensive agents, potentially altering efficacy or safety. Individuals scheduled for surgery should inform their surgeon of steroid use, as stress dosing may be required. Storage instructions recommend keeping the strip in a dry place below 30°C and out of reach of children. For comprehensive prescribing information, consult the product label or a licensed pharmacist.

Frequently Asked Questions

Q: What condition does Defcort 30 mg treat?

A: It is indicated for severe allergic reactions, including chronic urticaria, angioedema, and other immune‑mediated skin or systemic responses that require systemic corticosteroid therapy.

Q: How quickly does the medication work?

A: Most patients notice symptom relief within a few hours after the first dose, with maximal anti‑inflammatory effect typically observed after one to two days of consistent use.

Q: Can I take Defcort with other allergy medicines?

A: Yes, it can be combined with antihistamines or mast cell stabilizers, but you should always consult your doctor to avoid potential interactions.

Q: Is long‑term use safe?

A: Long‑term use requires medical supervision because of possible effects on blood pressure, glucose, bone health, and immune function; your physician will schedule regular check‑ups.

Q: Where can I find more detailed prescribing information?

A: Official prescribing details are available from the manufacturer’s label, the FDA database, or by speaking with a qualified healthcare professional.

Related Products

• Defcort (Deflazacort)
• Defcort 6 mg (Deflazacort)
• Defcort 12 mg (Deflazacort)
• Defcort 18 mg (Deflazacort)
• Defcort 24 mg (Deflazacort)
• Megalis Tablet (Tadalafil)
• Megalis 20 mg (Tadalafil)
• Omnacortil (Prednisolone)
• Omnacortil 5mg (Prednisolone)
• Omnacortil 10 mg (Prednisolone)
• Omnacortil 20 mg DT (Dispersible Tablets)
• Omnacortil 30 mg (Prednisolone)